Ambry Genetics Launches Illumina HiSeq 2000 Next Generation Sequencing Services

Ambry Genetics Launches Illumina HiSeq 2000 Next Generation Sequencing Services
Aliso Viejo, CA, USA, December 9, 2010 / b3c newswire / - Ambry Genetics, a global leader in genomic services to the healthcare and life sciences industries, announced today that it has officially launched their Illumina HiSeq 2000 Next Generation Sequencing Services. Ambry Genetics has been an early adapter of Illumina sequencing systems since 2007 and has extensive experience as a Certified Service Provider.


"We've continued to invest and develop our sequencing operations to become Illumina experts" said Ardy Arianpour, Vice President of Business Development at Ambry Genetics. "All of our customers are excited about the Illumina HiSeq because it expands our whole genome and exome sequencing services to the next level and gives them the opportunity to reduce their costs while providing more data. If Illumina is your preferred platform then we want to be your preferred sequencing provider. "

Ambry Genetics has been at the forefront of applying new sequencing technologies that best meet our clients' needs. A team of scientists routinely process libraries for all available applications ranging from small RNAs to whole genome DNA sequencing.   Having sequenced thousands of samples involving a wide range of species including human, mouse, bacteria, viruses, and plants, Ambry is known for its reputation for delivering quality data and service as well as the flexibility in customizing projects to meet the specific needs of researchers. Ambry Genetics will get your projects done right.


About Ambry Genetics - www.ambrygen.com

Ambry Genetics is a CAP-accredited and CLIA-certified commercial clinical laboratory headquartered in Aliso Viejo, California. Since the company's inception in 2000, it has become a leader in providing genetic services focused on clinical diagnostics and genomic services. Ambry has built a solid reputation for unparalleled service, and has been at the forefront of applying new technologies to the clinical molecular diagnostics market and advancements in disease research. To learn more about testing and services available through Ambry, visit www.ambrygen.com

 

 

Contact:
Jeff Owen
949-900-5542
[email protected] e-mail address is being protected from spambots. You need JavaScript enabled to view it 
 
 

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.